AnaptysBio, Inc. (0HFQ.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
As of 02:57PM BST. Market open.
| Previous close | 23.37 |
| Open | 24.24 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 21.97 - 24.24 |
| 52-week range | 21.97 - 24.24 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 1.999B |
| Beta (5Y monthly) | 0.13 |
| PE ratio (TTM) | 284.15 |
| EPS (TTM) | 0.31 |
| Earnings date | 02 May 2022 - 06 May 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Downgrade: Here's How Analysts See AnaptysBio, Inc. (NASDAQ:ANAB) Performing In The Near Term
One thing we could say about the analysts on AnaptysBio, Inc. ( NASDAQ:ANAB ) - they aren't optimistic, having just...
- Zacks
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal
AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.
© 2022 Yahoo. All rights reserved.
